Get the Stockscreener App
2.82
4.44%
0.12
After Hours:
2.82
C 4 Therapeutics Inc stock is traded at $2.82, with a volume of 2.13M.
It is up +4.44% in the last 24 hours and down -11.04% over the past month.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
See More
Previous Close:
$2.70
Open:
$2.63
24h Volume:
2.13M
Relative Volume:
1.05
Market Cap:
$275.17M
Revenue:
$35.95M
Net Income/Loss:
$-104.99M
P/E Ratio:
-2.0786
EPS:
-1.3567
Net Cash Flow:
$-99.30M
1W Performance:
+7.63%
1M Performance:
-11.04%
6M Performance:
+27.60%
1Y Performance:
+85.53%
1-Day Range:
$2.6001
$2.84
1-Week Range:
$2.30
$2.85
52-Week Range:
$1.085
$3.82
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Name
C 4 Therapeutics Inc
Sector
Industry
Phone
(617) 231-0700
Address
490 ARSENAL WAY, WATERTOWN
Compare CCCC vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.82 | 263.46M | 35.95M | -104.99M | -99.30M | -1.3567 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 113.62B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 82.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.12B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 43.60B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.54B | 606.42M | -1.28B | -997.58M | -6.403 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Initiated | TD Cowen | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-15-25 | Upgrade | Stephens | Equal-Weight → Overweight |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Dec-19-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-18-24 | Initiated | Stephens | Equal-Weight |
| Jan-29-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-13-23 | Upgrade | Stifel | Hold → Buy |
| Feb-24-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-24-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Underweight |
| Apr-28-22 | Initiated | Credit Suisse | Underperform |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-10-22 | Initiated | JP Morgan | Overweight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Nov-23-21 | Initiated | BofA Securities | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-27-20 | Initiated | BMO Capital Markets | Outperform |
| Oct-27-20 | Initiated | Jefferies | Buy |
View All
C 4 Therapeutics Inc Stock (CCCC) Latest News
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Analysts see significant upside in C4 Therapeutics (CCCC) stock - MSN
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update - marketbeat.com
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
CCCC Stock Price, Quote & Chart | C4 THERAPEUTICS INC (NASDAQ:CCCC) - ChartMill
C4 Therapeutics, Inc. advances pipeline as SVP Shagha Russell drives cemsidomide toward regulatory studies - Traders Union
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab for Relapsed/Refractory Multiple Myeloma - Investing News Network
C4 Therapeutics begins trial of cemsidomide with elranatamab - investing.com
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma - The Manila Times
New myeloma drug combo enters testing as C4 Therapeutics doses first patient - Stock Titan
Analysts See Significant Upside in C4 Therapeutics (CCCC) Stock - Insider Monkey
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aug Shorts: Is C4 Therapeutics Inc currently under institutional pressureGap Down & Expert Approved Momentum Ideas - baoquankhu1.vn
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - PharmiWeb.com
Mineralys Therapeutics reports inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 13, 2026 - BioSpace
C4 Therapeutics Details MOMENTUM Phase 2 Start, Eyes Near-Term Decision on EGFR Program at Barclays Confab - MarketBeat
Are you looking for a top momentum pick? Why C4 Therapeutics, Inc. (CCCC) is a great choice - MSN
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
CCCC SEC FilingsC4 Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact (NASDAQ:CCCC) - Seeking Alpha
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
C4 Therapeutics (CCCC) Well Positioned With Cemsidomide Trial Data - Finviz
C4 Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
CCCC (NASDAQ: CCCC) notice to sell 101,175 shares via option exercise on 03/09/2026 - Stock Titan
Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics, Inc. to join Barclays global healthcare conference fireside chat - Traders Union
Why C4 Therapeutics Inc. stock is popular among millennials2026 Trading Volume Trends & Fast Moving Stock Trade Plans - Naître et grandir
C4 Therapeutics Maps Accelerated Approval Path for Myeloma Drug Cemsidomide at TD Cowen Conference - MarketBeat
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Vera Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Fulcrum Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice - Yahoo Finance
C 4 Therapeutics Inc Stock (CCCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):